© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Lenvatinib Mesylate serves as a targeted therapy used in medical practice, recognized for its function as a tyrosine kinase inhibitor. People working with this compound observe its widespread application in cancer therapy, particularly for thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma. In pharma research and manufacturing settings, this agent does not resemble the broad-acting cytotoxics of earlier eras—its specificity comes from selective binding to the vascular endothelial growth factor receptors, along with other growth factor receptors.
At the molecular level, Lenvatinib Mesylate is defined with a formula of C21H19ClN4O4 · CH4O3S. The material forms a mesylate salt of the base molecule, which improves its solubility and handling characteristics for pharmaceutical production. Lenvatinib, the active ingredient, presents itself with a fairly complex heterocyclic structure that incorporates chlorine, nitrogen, and oxygen atoms, contributing to its robust receptor affinity. Its molecular weight reaches approximately 522.93 g/mol, and this figure, grounded in research data, provides guidance for tasks like stoichiometric calculation and solution preparation in chemistry labs.
Lenvatinib Mesylate appears in the form of a white to off-white powder or crystalline solid under standard laboratory conditions. On occasion, it takes on a flaky or pearly appearance depending on how it’s processed and the humidity level of the storage area. The material carries a specific density of about 1.4 g/cm³. In practice, technicians find dissolution rates reliable, with the raw material forming stable solutions in water and dimethyl sulfoxide (DMSO). No liquid version arrives from suppliers, as the solid form best fits synthesis, transport, and long-term storage priorities. Laboratory experience reveals that under a microscope, crystals hold their form even after gentle heating.
Importers often rely on the Harmonized System (HS) Code 2934999099 when shipping Lenvatinib Mesylate across international boundaries. Knowledge of this code speeds up customs processing, ensures accurate tariff assignment, and keeps shipping records consistent with global standards. In the storerooms of pharmaceutical producers, the material falls under controlled access due to its dual status: valuable as a raw material and potentially hazardous due to its bioactive properties.
Based on research, Lenvatinib Mesylate qualifies as hazardous to human health when mishandled. Chemists wear full personal protective equipment—lab coats, goggles, gloves—during weighing, mixing, or packaging steps. The powder form disperses in air quickly, increasing the risk of respiratory exposure, so fume hoods often see use during manipulation. Material Safety Data Sheet (MSDS) entries warn against ingestion, inhalation, or skin contact. Disposal procedures strictly control waste streams to protect environmental health, avoiding waterway contamination. Facilities document all raw material inventory to enable rapid traceback during regulatory inspections or product recalls.
Researchers and formulation scientists appreciate the solid state of Lenvatinib Mesylate for its stability and ease of measurement. The ability to produce precise dosages starts at the raw material level. As powders, flakes, or crystals, Lenvatinib Mesylate integrates directly into tablet-presses or capsule-fillers without the unpredictable separation seen in liquid or oily substances. Across the pharmaceutical supply chain, this property provides consistent dosing accuracy and long shelf life, supporting high standards in both research and commercial products.
Operational best practices for handling Lenvatinib Mesylate focus on training staff in chemical hygiene, maintaining secure supply chains, and applying rigorous environmental controls during all stages of production. Automated powder handling and enclosed transfer systems reduce direct human exposure. Facilities deploy storage rooms with humidity and temperature controls to maintain the compound’s crystalline integrity, while regular environmental monitoring addresses any risk of airborne contamination. Batch tracking, comprehensive documentation, and early hazard identification round out the approach.
Lenvatinib Mesylate demonstrates how detailed focus on physical characteristics supports safe, effective cancer therapies. The handling routines, safety measures, and process controls in the chemistry lab connect directly with quality medicines in the hospital. Raising awareness about the chain of care from raw material to therapeutic agent should stay a priority, encouraging shared responsibility at every step—from the chemical supplier all the way to the clinician and the patient.
